Tandem Diabetes Care (Nasdaq:TNDM) announced today that it kicked off the U.S. commercial launch of its Mobi insulin patch pump.
The San Diego-based company says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable automated insulin delivery (AID) system. It received FDA clearance for people with diabetes ages six and up in July 2023.
Tandem said today that it began taking orders and shipping Mobi to eligible U.S. customers.
Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the existing Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve.
The system features the same Control-IQ technology that powers the established t:slim X2. Control-IQ, an advanced hybrid closed-loop automated insulin delivery feature, predicts and helps prevent high and low blood sugar. It leads to improved time in range throughout the day and night.
“This tiny, wearable pump exceeded the expectations of users from an early access program, and we are thrilled to begin offering this exciting new technology to more people in the diabetes community,” said John Sheridan, Tanndem president and CEO. “With this launch, we are executing on our strategy to offer a differentiated portfolio of durable insulin pumps, providing choice, along with new options in wearability.”
Other features of the Tandem Mobi system
Mobi has compatibility with all existing Tandem-branded infusion sets manufactured by Convatec. That includes a new five-inch tubing option made just for Mobi. Infusion sets allow users to temporarily disconnect from pumps for convenience. The company offers more than 30 mix-and-match infusion site and tubing length combinations.
Users can control their Mobi pump through a compatible iPhone with a mobile iOS application. The system currently has compatibility with the Dexcom G6 continuous glucose monitor (CGM) and Tandem plans for more integration. First, the company expects G7 integration in the second quarter of this year, followed by the Abbott FreeStyle Libre 3.
Tandem recently made great strides on its CGM integration, becoming the first to pair an automated insulin delivery to Dexcom’s latest technology when it integrated G7 into the t:slim X2 in December. The company then became the first to add Abbott’s CGM to AID technology by integrating the FreeStyle Libre 2 Plus into the t:slim X2.
Additional Mobi features include water resistance to a depth of eight feet for up to two hours. The system has a physical button that allows users to deliver insulin boluses without their iPhone as well. Finally, the system uses modern wireless charging and has remote software update capabilities.
Tandem plans to process orders on a first-come, first-served basis. It targets users who meet specific eligibility requirements, including use of G6, with initial shipments.